Pfizer and Takeda deals put spotlight back on value-based pricing programs
Efforts to pay for a drug based on its value were limited by logistics, but recent deals for cancer drugs could be a step forward
Pharma
Global warning: pharma’s role in the climate crisis
With COP26 imminent, what lessons can the pharma sector learn about its environmental impact and...
Valneva could outsource Covid-19 vaccine manufacturing in response to demand
Valneva maps authorisation and manufacturing plans on the heels of positive Phase III Covid-19 vaccine...
The ethics of vaccine boosters
With the variance in Covid-19 vaccine access, what are the ethics of promoting third booster...
Oral Covid-19 drugs: Merck’s molnupiravir and its closest rivals
With Merck and Ridgeback revealing their topline Phase III data, the stage is set for...
Moderna tops hiring leaderboard for August 2021
We've analysed the largest pharmaceutical companies tracked by GlobalData to see which have had the biggest recruitment drives recently.
Why has the WHO asked governments to delay Covid-19 booster jabs?
While booster shots will likely be needed long-term, the WHO has argued that first jabs for poorer nations should be prioritised.
Waning Covid-19 vaccine efficacy: what does the data show?
While Covid-19 vaccines’ protection does appear to wane, most experts agree that universal booster rollouts aren’t needed yet.
Five pharma cybersecurity breaches to know and learn from
The transition to digital, expedited by the Covid-19 pandemic, has opened up new cybersecurity concerns.
CinnaGen protein subunit Covid-19 vaccine Phase III results likely within two months
Race to be the first widely distributed protein subunit Covid-19 vaccine heats up with Vaxine nipping at Novavax’s heels.
Unmet needs: a brief history of ALS and its sparse pipeline
With an experimental treatment showing promise, Kezia Parkins charts the history of ALS and its treatments.
